Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma.

Importance Coronavirus disease 2019 (COVID-19) is a pandemic with no specific therapeutic agents and substantial mortality. It is critical to find new treatments. Objective To determine whether convalescent plasma transfusion may be beneficial in the treatment of critically ill patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Design, Setting, and Participants Case series of 5 critically ill patients with laboratory-confirmed COVID-19 and acute respiratory distress syndrome (ARDS) who met the following criteria: severe pneumonia with rapid progression and continuously high viral load despite antiviral treatment; Pao2/Fio2 <300; and mechanical ventilation. All 5 were treated with convalescent plasma transfusion. The study was conducted at the infectious disease department, Shenzhen Third People's Hospital in Shenzhen, China, from January 20, 2020, to March 25, 2020; final date of follow-up was March 25, 2020. Clinical outcomes were compared before and after convalescent plasma transfusion. Exposures Patients received transfusion with convalescent plasma with a SARS-CoV-2-specific antibody (IgG) binding titer greater than 1:1000 (end point dilution titer, by enzyme-linked immunosorbent assay [ELISA]) and a neutralization titer greater than 40 (end point dilution titer) that had been obtained from 5 patients who recovered from COVID-19. Convalescent plasma was administered between 10 and 22 days after admission. Main Outcomes and Measures Changes of body temperature, Sequential Organ Failure Assessment (SOFA) score (range 0-24, with higher scores indicating more severe illness), Pao2/Fio2, viral load, serum antibody titer, routine blood biochemical index, ARDS, and ventilatory and extracorporeal membrane oxygenation (ECMO) supports before and after convalescent plasma transfusion. Results All 5 patients (age range, 36-65 years; 2 women) were receiving mechanical ventilation at the time of treatment and all had received antiviral agents and methylprednisolone. Following plasma transfusion, body temperature normalized within 3 days in 4 of 5 patients, the SOFA score decreased, and Pao2/Fio2 increased within 12 days (range, 172-276 before and 284-366 after). Viral loads also decreased and became negative within 12 days after the transfusion, and SARS-CoV-2-specific ELISA and neutralizing antibody titers increased following the transfusion (range, 40-60 before and 80-320 on day 7). ARDS resolved in 4 patients at 12 days after transfusion, and 3 patients were weaned from mechanical ventilation within 2 weeks of treatment. Of the 5 patients, 3 have been discharged from the hospital (length of stay: 53, 51, and 55 days), and 2 are in stable condition at 37 days after transfusion. Conclusions and Relevance In this preliminary uncontrolled case series of 5 critically ill patients with COVID-19 and ARDS, administration of convalescent plasma containing neutralizing antibody was followed by improvement in their clinical status. The limited sample size and study design preclude a definitive statement about the potential effectiveness of this treatment, and these observations require evaluation in clinical trials.

[1]  M. Radosevich,et al.  Treatment of severe acute respiratory syndrome with convalescent plasma. , 2003, Hong Kong medical journal = Xianggang yi xue za zhi.

[2]  P. Chan,et al.  Use of convalescent plasma therapy in SARS patients in Hong Kong , 2004, European Journal of Clinical Microbiology and Infectious Diseases.

[3]  P. Chan,et al.  Experience of using convalescent plasma for severe acute respiratory syndrome among healthcare workers in a Taiwan hospital , 2005, The Journal of antimicrobial chemotherapy.

[4]  Yi Guan,et al.  Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia , 2006, Nature Medicine.

[5]  Y. Guan,et al.  Treatment with convalescent plasma for influenza A (H5N1) infection. , 2007, The New England journal of medicine.

[6]  Kwok-Hung Chan,et al.  Convalescent Plasma Treatment Reduced Mortality in Patients With Severe Pandemic Influenza A (H1N1) 2009 Virus Infection , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  Philip Smith,et al.  Administration of Brincidofovir and Convalescent Plasma in a Patient With Ebola Virus Disease. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  L. Blanch,et al.  Assessment of PaO2/FiO2 for stratification of patients with moderate and severe acute respiratory distress syndrome , 2015, BMJ Open.

[9]  L. Blanch,et al.  Assessment of PaO2/FiO2 for stratification of patients with moderate and severe acute respiratory distress syndrome , 2015, BMJ Open.

[10]  W. Lim,et al.  The Effectiveness of Convalescent Plasma and Hyperimmune Immunoglobulin for the Treatment of Severe Acute Respiratory Infections of Viral Etiology: A Systematic Review and Exploratory Meta-analysis , 2014, The Journal of infectious diseases.

[11]  Elizabeth L. Beam,et al.  The Use of TKM-100802 and Convalescent Plasma in 2 Patients With Ebola Virus Disease in the United States. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  A. Chakraborty,et al.  Enhanced clearance of HIV-1–infected cells by broadly neutralizing antibodies against HIV-1 in vivo , 2016, Science.

[13]  P. Horby,et al.  Evaluation of Convalescent Plasma for Ebola Virus Disease in Guinea. , 2016, The New England journal of medicine.

[14]  Honglin Chen,et al.  A multimechanistic antibody targeting the receptor binding site potently cross-protects against influenza B viruses , 2017, Science Translational Medicine.

[15]  Kok-Gan Chan,et al.  Viral Load and Sequence Analysis Reveal the Symptom Severity, Diversity, and Transmission Clusters of Rhinovirus Infections , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[16]  Honglin Chen,et al.  An IgM antibody targeting the receptor binding site of influenza B blocks viral infection with great breadth and potency , 2019, Theranostics.

[17]  Toshiaki Iba,et al.  The unique characteristics of COVID-19 coagulopathy , 2020, Critical Care.

[18]  C. Bode,et al.  First do no harm—beware the risk of therapeutic plasma exchange in severe COVID-19 , 2020, Critical Care.

[19]  Jing Yuan,et al.  Viral Architecture of SARS-CoV-2 with Post-Fusion Spike Revealed by Cryo-EM , 2020, bioRxiv.

[20]  Y. Hu,et al.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China , 2020, The Lancet.

[21]  S. Kaveri,et al.  Adjunct Immunotherapies for the Management of Severely Ill COVID-19 Patients , 2020, Cell Reports Medicine.

[22]  Hongzhou Lu,et al.  Drug treatment options for the 2019-new coronavirus (2019-nCoV). , 2020, Bioscience trends.

[23]  Lei Liu,et al.  Evaluating the accuracy of different respiratory specimens in the laboratory diagnosis and monitoring the viral shedding of 2019-nCoV infections , 2020, medRxiv.

[24]  R. Faillace,et al.  Compassionate use of others’ immunity — understanding gut microbiome in Covid-19 , 2020, Critical Care.

[25]  Zunyou Wu,et al.  Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. , 2020, JAMA.

[26]  Long-gen Liu,et al.  Non-optimal effectiveness of convalescent plasma transfusion and hydroxychloroquine in treating COVID-19: a case report , 2020, Virology Journal.

[27]  Yuan Shi,et al.  Convalescent plasma as a potential therapy for COVID-19 , 2020, The Lancet Infectious Diseases.

[28]  Frank Grosveld,et al.  A human monoclonal antibody blocking SARS-CoV-2 infection , 2020, Nature Communications.